MR-guided focused ultrasound (MRgFUS) is a promising noninvasive treatment showing effectiveness in alleviating pain from bone metastases in cancer patients.
A multicenter study involving 31 patients demonstrated a significant reduction in pain scores (from 5.9 to 1.8) and decreased opioid usage after treatment, with 72% of patients reporting pain improvement.
The procedure was found to be safe, with no severe device-related complications recorded, indicating that MRgFUS could be a viable palliative option for managing cancer-related pain.
Objective: To assess outcomes at 6 and 12 months after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for symptomatic uterine leiomyomas.